| scholarly article | Q13442814 |
| P50 | author | Enrique Brandan | Q39493202 |
| Carlos P. Vio | Q51553246 | ||
| P2093 | author name string | Daniel Cabrera | |
| Claudio Cabello-Verrugio | |||
| María Gabriela Morales | |||
| P2860 | cites work | Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals | Q24648246 |
| Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA | Q28298502 | ||
| Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells | Q33559684 | ||
| Angiotensin II and renal fibrosis. | Q34376512 | ||
| Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair | Q34437758 | ||
| Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm | Q34553566 | ||
| Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states | Q35110459 | ||
| Vascular angiotensin II actions mediated by angiotensin II type 2 receptors | Q35686201 | ||
| Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration | Q35748197 | ||
| Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse | Q36096234 | ||
| The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease | Q36335340 | ||
| Anti-inflammatory properties of drugs acting on the renin-angiotensin system | Q36338078 | ||
| Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. | Q36663074 | ||
| Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. | Q37192537 | ||
| Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis | Q37201619 | ||
| Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? | Q37265882 | ||
| Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? | Q37373460 | ||
| The angiotensin II type 2 receptor in cardiovascular disease | Q37622575 | ||
| CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy | Q39493006 | ||
| Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type β receptors and the JNK pathway. | Q39641396 | ||
| CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. | Q39855226 | ||
| Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation | Q40038399 | ||
| A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. | Q40136056 | ||
| Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-beta and its binding to class IA PI3K in vascular smooth muscle cells | Q40299036 | ||
| Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation | Q40506933 | ||
| Expression of connective tissue growth factor in experimental rat and human liver fibrosis | Q40926848 | ||
| Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease | Q41974579 | ||
| Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes. | Q41988029 | ||
| Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy | Q42521370 | ||
| Antifibrotic effects of suramin in injured skeletal muscle after laceration | Q42802337 | ||
| Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol | Q42938849 | ||
| Functional improvement of dystrophic muscle by myostatin blockade. | Q44234792 | ||
| Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen | Q44644827 | ||
| Renal and hormonal effects of water deprivation in late-term pregnant rats | Q44995576 | ||
| Blood pressure maintenance in NHE3-deficient mice with transgenic expression of NHE3 in small intestine | Q45154807 | ||
| Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle | Q46542641 | ||
| Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy. | Q46725755 | ||
| Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation | Q47375411 | ||
| Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis | Q47701595 | ||
| Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis | Q47817504 | ||
| Ischaemia-reperfusion modulates inflammation and fibrosis of skeletal muscle after contusion injury. | Q50581803 | ||
| AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney. | Q52010401 | ||
| Connective tissue growth factor/CCN2 overexpression in mouse synovial lining results in transient fibrosis and cartilage damage | Q64377854 | ||
| Expression of connective tissue growth factor in human renal fibrosis | Q74462450 | ||
| [Effect of exogenous interferon gamma on the healing of injured skeletal muscle following injury] | Q83085206 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 4 | |
| P304 | page(s) | 752-764 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles | |
| P478 | volume | 16 |
| Q35138448 | ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. |
| Q39629598 | Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis |
| Q89682685 | Angiotensin (1-7) Decreases Myostatin-Induced NF-κB Signaling and Skeletal Muscle Atrophy |
| Q89684513 | Angiotensin II blockade had no effect on range of motion after total knee arthroplasty: a retrospective review |
| Q64246020 | Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients |
| Q36856035 | Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas |
| Q38956473 | Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism |
| Q61813508 | Angiotensin-(1-7) exerts a protective action in a rat model of ventilator-induced diaphragmatic dysfunction |
| Q35861077 | Angiotensin-dependent autonomic dysregulation precedes dilated cardiomyopathy in a mouse model of muscular dystrophy |
| Q26996208 | Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system |
| Q47776900 | Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors |
| Q50632027 | CCN family protein 2 (CCN2) promotes the early differentiation, but inhibits the terminal differentiation of skeletal myoblasts. |
| Q38103213 | Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers. |
| Q38258015 | Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions |
| Q35053205 | Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. |
| Q52564618 | Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. |
| Q92097301 | Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice |
| Q92798645 | Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model |
| Q35141755 | Endotoxin induces fibrosis in vascular endothelial cells through a mechanism dependent on transient receptor protein melastatin 7 activity. |
| Q42932656 | Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2. |
| Q54192199 | Expression of the Mas receptor is upregulated in skeletal muscle wasting. |
| Q89846141 | HIF-hypoxia signaling in skeletal muscle physiology and fibrosis |
| Q41479479 | High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis. |
| Q89357638 | Identification of potential markers of fatal hypothermia by a body temperature-dependent gene expression assay |
| Q50994524 | Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). |
| Q91627444 | Muscle wasting: A review of exercise, classical and non-classical RAS axes |
| Q42836794 | Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy |
| Q46860194 | Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway |
| Q38375202 | Renin-angiotensin system: an old player with novel functions in skeletal muscle |
| Q38096495 | Role of proteoglycans in the regulation of the skeletal muscle fibrotic response. |
| Q38905039 | SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β. |
| Q89171886 | Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin-proteasome system and oxidative stress |
| Q46924901 | The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-β1 induced by AngII in mouse skeletal muscle. |
| Q90546431 | The Emerging Roles of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 in Skeletal Muscle Redox Signaling and Metabolism |
| Q54189352 | The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice. |
| Q37526343 | The link between stress disorders and autonomic dysfunction in muscular dystrophy |
| Q48100107 | The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle |
| Q38225126 | Therapeutic approaches to skeletal muscle repair and healing. |
| Q39185363 | Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle. |
Search more.